IFx-Hu2.0 with pembrolizumab for advanced Merkel cell carcinoma
Treatments studied
Part of Cancer, Infections clinical trials.
This trial tests a new drug, IFx-Hu2.0, given alongside the immunotherapy pembrolizumab (Keytruda) for people with advanced or spreading Merkel cell carcinoma (MCC). The goal is to see if the combination helps shrink tumors and slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have Merkel cell carcinoma that has come back or spread and cannot be removed by surgery (Stage III or IV).
- You must have at least one tumor that can be injected (at least 3 mm in size).
- You must not have received any previous immunotherapy (like pembrolizumab, avelumab, ipilimumab, or nivolumab).
- You must be willing to provide a tumor sample from a previous biopsy or have a new one done.
- You must not be pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental vaccine (IFx-Hu2.0) followed by the immunotherapy drug pembrolizumab in people with advanced Merkel cell carcinoma who have not been treated with checkpoint inhibitors before. The goal is to see if this combination helps shrink or control the cancer.
This trial is testing a new drug, BH3120, that boosts the immune system's ability to fight cancer. It's for people with advanced solid tumors that haven't responded to standard treatments. The drug may be given alone or with another immunotherapy drug called pembrolizumab.
This trial tests a new combination for people with advanced Merkel cell carcinoma (MCC), a rare skin cancer. It combines the immunotherapy drug pembrolizumab with standard chemotherapy (cisplatin or carboplatin plus etoposide). The goal is to see if this combination shrinks or controls the cancer better than chemotherapy alone.
This study tests a combination of two medicines—an oral therapy (ASTX727) and an immunotherapy (retifanlimab)—for people with advanced Merkel cell carcinoma that has not responded to prior immunotherapy. The goal is to see if this new combination can help shrink or control the cancer.
This program gives access to an experimental drug called IFx-Hu2.0 for people with advanced cancer who have no other treatment options. It aims to see if the drug can help fight the cancer.
This trial tests pembrolizumab (an immune therapy) given before surgery to shrink Merkel cell carcinoma and improve outcomes. Participants also have extra tumor biopsies to study biomarkers, which may help explain who benefits most.
Hear when a new Advanced Or Metastatic Merkel Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.